Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Urinary Bladder" returned 8 results:


Multi-center Phase 2 Trial of Single-agent Amrubicin as second-line therapy in patients with Advanced/Metastatic Refractory Urothelial Carcinoma
Principal Investigator(s): Matthew Galksy

A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent
Principal Investigator(s): Dr. Matthew Galsky

A Randomized, Phase 2, Open Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Principal Investigator(s): Simon J. Hall

Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma
Principal Investigator(s): Matthew Galsky

A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer
Principal Investigator(s): Matthew Galsky

Phase II Trial of Gemcitabine, Cisplatin, plus Ipilimumab as First-line Treatment for Patients with Metastatic Urothelial Carcinoma
Principal Investigator(s): Matthew Galsky

A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel,
Principal Investigator(s): Dr. Matthew Galsky

A Phase I, open-label, multicenter, dose escalation study of oral BGJ398, a pan FGFR kinase inhibitor, in adult patients with advanced solid malignancies
Principal Investigator(s): Dr. Matthew Galsky